<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04967014</url>
  </required_header>
  <id_info>
    <org_study_id>HM-ESOL-101</org_study_id>
    <nct_id>NCT04967014</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Pharmacodynamic/Pharmacokinetic Characteristics of HIP2101 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Multiple-Dose, Crossover Phase 1 Clinical Trial to Evaluate the Safety and Pharmacodynamic/Pharmacokinetic Characteristics After Oral Administration of HIP2101 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 Study to Evaluate the Safety and Pharmacodynamic/Pharmacokinetic Characteristics of&#xD;
      HIP2101 in Healthy Volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Open-label, Multiple-dose, Crossover Phase 1 Clinical Trial to Evaluate the&#xD;
      Safety and Pharmacodynamic/Pharmacokinetic Characteristics after Oral Administration of&#xD;
      HIP2101 in Healthy Adult Volunteers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Actual">June 18, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration time with integrated gastric pH&gt;4 / 24hr</measure>
    <time_frame>0-24hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median 24 hr gastric pH</measure>
    <time_frame>0-24hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent decrease from baseline in integrated gastric acidity for 24-hour interval after dose</measure>
    <time_frame>0-24hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy Adult Volunteer</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I : RLD2104 Period II : HIP2104</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I : HIP2104 Period II : RLD2104</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIP2101</intervention_name>
    <description>Test drug</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RLD2101</intervention_name>
    <description>Reference drug</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers in the age between 19 and 50 years old.&#xD;
&#xD;
          -  Body mass index (BMI) in the range of 18 to 30 kg/m2 and weight 50.0kg to 90.0kg.&#xD;
&#xD;
          -  After fully hearing and understanding the details of this clinical trial, Subjects who&#xD;
             have willingness to sign of informed consent before the screening.&#xD;
&#xD;
          -  Subject who are eligible from physical examination, clinical laboratory test by&#xD;
             investigators judgment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gastrointestinal disorders (Crohn's disease or Acute/chronic pancreatitis) or&#xD;
             gastrointestinal surgery (except for simple cecal or hernia surgery) which may affect&#xD;
             the safety and pharmacokinetic evaluation of test drug.&#xD;
&#xD;
          -  Subjects who have a history of hypersensitivity or clinically significant&#xD;
             hypersensitivity to investigational product or the same component or other drugs.&#xD;
&#xD;
          -  Aspartate aminotransferase and alanine aminotransferase exceed 2 times the upper limit&#xD;
             of normal range from screening laboratory results before randomization.&#xD;
&#xD;
          -  Subject who continues to drink (21 units / week, 1 unit = 10 g of pure alcohol) within&#xD;
             6 months before the first administration or who cannot abstain from consent to&#xD;
             post-study visit.&#xD;
&#xD;
          -  Heavy smoker (&gt;10 cigarettes/day).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chungbuk University Hospital</name>
      <address>
        <city>Cheongju-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

